Click Holdings Limited (NASDAQ:CLIK) Sees Significant Decline in Short Interest

Posted by Francis Steltz on Jun 14th, 2026

Click Holdings Limited (NASDAQ:CLIK – Get Free Report) was the target of a significant decline in short interest during the month of May. As of May 29th, there was short interest totaling 50,211 shares, a decline of 48.6% from the May 14th total of 97,673 shares. Based on an average daily volume of 1,195,878 shares, the days-to-cover ratio is currently 0.0 days. Approximately 4.4% of the company’s stock are short sold.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Click stock. Renaissance Technologies LLC acquired a new position in Click Holdings Limited (NASDAQ:CLIK – Free Report) in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 14,200 shares of the company’s stock, valued at approximately $25,000. Renaissance Technologies LLC owned 1.23% of Click as of its most recent filing with the Securities & Exchange Commission.

Analyst Ratings Changes

Several equities analysts have issued reports on CLIK shares. Wall Street Zen raised shares of Click to a “hold” rating in a report on Saturday. Weiss Ratings reiterated a “sell (d)” rating on shares of Click in a research note on Friday, March 27th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Sell”.

View Our Latest Report on CLIK

Click Trading Down 1.9%

Shares of NASDAQ:CLIK traded down $0.03 on Friday, hitting $1.58. 2,090,395 shares of the company were exchanged, compared to its average volume of 2,789,769. Click has a 1-year low of $1.32 and a 1-year high of $15.90. The stock’s 50 day moving average price is $2.12 and its 200 day moving average price is $3.60.

Click (NASDAQ:CLIK – Get Free Report) last posted its earnings results on Monday, May 11th. The company reported $0.10 earnings per share (EPS) for the quarter. The business had revenue of $3.79 million for the quarter.

About Click

(Get Free Report)

Click Therapeutics, Inc (NASDAQ: CLIK) is a clinical-stage digital therapeutics company developing software-based treatments for neurological, psychiatric and chronic diseases. Its platform delivers prescription digital therapies via mobile and web applications, combining evidence-based cognitive behavioral interventions, digital monitoring tools and patient engagement techniques. Click’s approach is designed to complement or extend traditional pharmacological and behavioral treatments for conditions such as major depressive disorder, insomnia and tobacco use disorder.

Founded in 2014, Click has progressed multiple programs through randomized controlled trials and regulatory review.